spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  Interleukin-1 

 HSMN NewsFeed - 3 Jul 2025
Novartis Provides Update on Phase III GCAptAIN Study of Cosentyx(R) in Giant Cell Arteritis (GCA)
Biopharmaceuticals
 HSMN NewsFeed - 31 Mar 2025
Lomond Therapeutics Completes Second and Third Closings and adds Two New Investors
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 25 Oct 2024
Lilly's EBGLYSS(TM) (lebrikizumab-lbkz) Demonstrated Meaningful Improvement in Skin Clearance and Itch Relief in the Majority of Patients with Moderate-To-Severe Atopic Dermatitis Who Discontinued Dupilumab
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 31 Oct 2023
FDA Approves Novartis Cosentyx(R) as the First New Biologic Treatment Option for Hidradenitis Suppurativa Patients in Nearly a Decade
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Jun 2022
Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 10 May 2022
Genascence Announces First Close in Series A Financing led by Pacira BioSciences and Expands Board of Directors and Scientific Advisory Board
Regenerative Medicine Orthopaedic Venture Capital
 HSMN NewsFeed - 29 Apr 2022
OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Apr 2022
Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE(TM) Molecule
Biopharmaceuticals Licensing
 HSMN NewsFeed - 17 Dec 2021
OncoSec Announces Changes to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Oct 2021
FDA Expands Approval of Dupixent(R) (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Apr 2021
OncoSec Receives CE Mark Certification for its Commercial Electroporation Device "GenPulse(TM)" for the Treatment of Solid Tumors
Devices Oncology Regulatory
 HSMN NewsFeed - 18 Feb 2021
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Feb 2021
OncoSec Strengthens Management Team With Two New Appointments
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Jan 2021
Werewolf Therapeutics Completes $72 Million Series B Financing to Advance a Novel Class of Cancer Biotherapeutics to the Clinic
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 12 Oct 2020
OncoSec Announces Appointment of Sandra Aung, Ph.D. as Senior Vice President, Chief Clinical Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Jun 2020
Dupixent(R) (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 8 Jan 2020
Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life-Saving Treatment for Post-Lung Transplant Patients to the Altavant Pipeline
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 6 Aug 2019
Dupixent(R) (dupilumab) Approved by European Commission for Adolescents with Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 27 Jun 2019
OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 7 May 2019
Dupixent(R) (dupilumab) Approved for Severe Asthma by European Commission
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Apr 2019
OncoSec Appoints Industry Veteran Margaret R. Dalesandro, Ph.D., to its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Apr 2019
OncoSec Announces New Technology to Treat Deep Visceral Lesions with IL-12
Biopharmaceuticals Oncology Drug Delivery
 HSMN NewsFeed - 1 Apr 2019
OncoSec Announces Advanced Therapy Medicinal Product Classification from the EMA for TAVO(TM) in Refractory Metastatic Melanoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 1 Mar 2019
CHMP Recommends Approval of Dupixent(R) (dupilumab) for Asthma Indication
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Dec 2018
OncoSec Announces Appointment Of Joon Kim, J.D., To Board Of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Nov 2018
OncoSec Appoints Robert Ward to its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Oct 2018
OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Oct 2018
FDA Approves Asthma Indication for Dupixent(R) (dupilumab)
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Sep 2018
OncoSec Announces $15 Million At Market Investment from Alpha Holdings, Inc.
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 28 Aug 2018
OncoSec Appoints Alain Algazi, MD, as Clinical Strategic Advisor
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Jul 2018
OncoSec Appoints Robert W. Ashworth, Ph.D. as Vice President, Regulatory
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 May 2018
Lilly Announces Agreement To Acquire ARMO BioSciences
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 2 Mar 2018
FDA to Review DUPIXENT(R) (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jan 2018
Novartis new data reinforces superiority of Cosentyx(R) versus Stelara(R) in achieving skin clearance for psoriasis patients
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 16 Nov 2017
Sobi(TM) - First Patient Randomised in a Phase 3 Study Evaluating Safety and Efficacy of Anakinra in the Treatment of Still's Disease
Biopharmaceuticals
 HSMN NewsFeed - 12 Oct 2017
Ortho Dermatologics Announces Two-Year Findings From Pivotal Phase 3 Study Of SILIQ(TM) (brodalumab) Injection Data Demonstrating Long-Term Efficacy Profile
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 29 Aug 2017
ARMO BioSciences Raises $67 Million in a Series C-1 Financing
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 27 Jul 2017
Valeant Announces U.S. Launch of SILIQ(TM) (brodalumab) Injection
Biopharmaceuticals Dermatology Product Launch
 HSMN NewsFeed - 17 Jul 2017
Medicenna Bolsters Management Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Apr 2017
Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ(TM) (Brodalumab) As The Lowest Priced Injectable Biologic For Moderate-To-Severe Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 16 Feb 2017
Valeant Receives FDA Approval Of SILIQ(TM) (Brodalumab) For Moderate-To-Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 7 Oct 2016
Rigel Expands Leadership Team in Research and Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jul 2016
Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe
Biopharmaceuticals Licensing
 HSMN NewsFeed - 27 Apr 2016
Novartis Receives Three FDA Breakthrough Therapy Designations for IlaristTo Treat Rare Types of Periodic Fever Syndromes
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Apr 2016
European Medicines Agency Grants Accelerated Assessment of Marketing Authorization Application for Xilonix(TM), XBiotech’s True Human(TM) Therapeutic Antibody Treatment for Advanced Colorectal Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Feb 2016
Genentech Provides Update On Two Identical Phase III Studies Of Lebrikizumab In People With Severe Asthma
Biopharmaceuticals
 HSMN NewsFeed - 25 Jan 2016
Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 16 Jan 2016
Novartis receives two new FDA approvals for Cosentyx(R) (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Sep 2015
Valeant And AstraZeneca To Partner On Brodalumab
Biopharmaceuticals Dermatology Licensing Distribution
 HSMN NewsFeed - 11 Aug 2015
Celgene Receives Antitrust Clearance for Receptos Acquisition
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 Jul 2014
Abide Therapeutics Appoints Nancy Thornberry to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Dec 2013
Takeda Announces Exclusive License and Option Agreement with Natrogen for Development of Natura-alpha for Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology Licensing
 HSMN NewsFeed - 13 Dec 2013
Neumedicines Presents HemaMax(TM) Clinical Data at the ASH Conference
Biopharmaceuticals
 HSMN NewsFeed - 22 Jul 2013
Receptos Announces Appointment of Erle T. Mast as Director
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 May 2013
Novartis drug Ilaris(R) approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis
Biopharmaceuticals. FDA
 HSMN NewsFeed - 26 Mar 2013
ZIOPHARM Terminates Development of Palifosfamide in Metastatic Soft Tissue Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jun 2011
XOMA Appoints Paul Rubin, M.D. as Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Oct 2010
New Data Demonstrate Treatment With STELARA(R) (Black Triangle Drug) (ustekinumab) Results in Sustained Improvements in Psoriasis Severity and Quality of Life up to Three Years
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 19 Jul 2010
Phage Pharmaceuticals Appoints David Jackson as Vice President, Operations Planning
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 May 2010
STELARA(TM) Significantly Improves Symptoms of Depression, Anxiety and Health-Related Quality of Life in Patients With Moderate to Severe Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 14 Jan 2010
STELARA(TM) (ustekinumab) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 23 Sep 2009
Janssen-Cilag's STELARA(R) (Black Triangle Drug) (ustekinumab) Approved by NICE for the Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 24 Jul 2009
Regeneron Receives European Medicines Agency Positive Opinion for Marketing Authorization of Rilonacept for the Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Jan 2009
New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Oct 2008
CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
Biopharmaceuticals
 HSMN NewsFeed - 6 Oct 2008
CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 18 Sep 2008
Findings From Landmark Study Show Ustekinumab Demonstrated Superior Efficacy to Enbrel(R) (Etanercept) in Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 4 Aug 2008
Expression Genetics Inc., Specializing in DNA/RNAi Delivery and Therapeutics, Completes $12M Series B Financing
Biopharmaceuticals Drug Delivery Venture Capital
 HSMN NewsFeed - 17 Jun 2008
FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 20 May 2008
Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 25 Mar 2008
ARCALYST(TM) (rilonacept), First and Only FDA-approved Treatment for Cryopyrin-Associated Periodic Syndromes (CAPS), Now Available in the United States
Biopharmaceuticals
 HSMN NewsFeed - 27 Feb 2008
FDA Approves Regeneron's ARCALYST(TM) (rilonacept) for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Feb 2008
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 10 Dec 2007
Osiris Therapeutics Reports Positive Results for Prochymal(TM) as a Rescue Agent in Pediatric Patients with End-Stage Graft vs. Host Disease
Regenerative Medicine
 HSMN NewsFeed - 4 Dec 2007
Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals FDA Regulatory
 HSMN NewsFeed - 3 Oct 2007
Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 8 Aug 2007
Rilonacept (IL-1 Trap) Granted FDA Priority Review for the Treatment of CAPS
Biopharmaceuticals
 HSMN NewsFeed - 8 Jun 2007
Regeneron Submits Biologics License Application to U.S. FDA for IL-1 Trap (Rilonacept) for Treatment of CAPS
Biopharmaceuticals
 HSMN NewsFeed - 4 May 2007
Abbott's Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 14 Apr 2007
ARIAD files claim against Amgen and Wyeth Alleging Infringement of NF-(kappa)B Patent by Enbrel(R) and Kineret(R)
Biopharmaceuticals Litigation
 HSMN NewsFeed - 12 Apr 2007
XOMA Announces Clinical Trial Plans for XOMA 052 in Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 14 Dec 2006
Quest Diagnostics Launches Test to Help Oncologists Predict Risk of Breast Cancer Recurrence in Women with Estrogen Receptor (ER)-Positive, Lymph Node- Negative Cancers
Diagnostics Oncology
 HSMN NewsFeed - 9 Dec 2006
Osiris Therapeutics Provides Update on Phase II Trial Evaluating PROCHYMAL(TM) for the Treatment of Acute Graft vs. Host Disease
Biopharmaceuticals
 HSMN NewsFeed - 9 Nov 2006
Osiris Therapeutics Reports Positive Phase II Results Using PROCHYMAL(TM) for the Treatment of Acute Graft vs. Host Disease
Biopharmaceuticals Regenerative Medicine
 HSMN NewsFeed - 18 Sep 2006
NEOPHARM Presents Updated CINTREDEKIN BESUDOTOX Phase I/II Median Survival Data at European Association of Neuro-Oncology (EANO) Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jun 2006
NeoPharm Announces PRECISE Trial Update
Biopharmaceuticals Drug Delivery Neurosurgery Oncology
 HSMN NewsFeed - 31 May 2006
Regeneron Receives Fast-Track Designation for the IL-1 Trap in CIAS1-Associated Periodic Syndromes (CAPS)
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 22

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 22 additional stories matching:
Interleukin-1
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!